PSYCHOSIS AND SCHIZOPHRENIA

Pharmacology and Therapeutics: Principles to Practice

Volumn , Issue , 2008, Pages 797-815

  Siegel, Steven J ^a   Dankert, Mary E ^a   Phillips, Jennifer M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70049109239     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3291-5.50058-5     Document Type: Chapter

References (148)

1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Washington, DC: American Psychiatric Association Text Revision.
2. C Arango, RW Buchanan, B Kirkpatrick and WT Carpenter (2004) The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry 19 21-26.
3. WT Carpenter Jr, DW Heinrichs and AM Wagman (1988) Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145 578-583.
4. AM Wagman, DW Heinrichs and WT Carpenter Jr (1987) Deficit and nondeficit forms of schizophrenia: neuropsychological evaluation. Psychiatry Res 22 319-330.
5. WT Carpenter Jr (1994) The deficit syndrome. Am J Psychiatry 151 327-329.
6. WS Fenton and TH McGlashan (1994) Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry 151 351-356.
7. DI Mayerhoff, AD Loebel, JM Alvir, et al. (1994) The deficit state in first-episode schizophrenia. Am J Psychiatry 151 1417-1422.
8. I Gottesman (1991) Schizophrenia Genesis: The Origins of Madness New York: Freeman
9. CM O'Tuathaigh, D Babovic, G O'Meara, et al. (2007) Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. Neurosci Biobehav Rev 31 60-78.
10. S Prathikanti and DR Weinberger (2005) Psychiatric genetics—the new era: genetic research and some clinical implications. Br Med Bull 73–74 107-122.
11. YL Battle, BC Martin, JH Dorfman and LS Miller (1999) Seasonality and infectious disease in schizophrenia: the birth hypothesis revisited. J Psychiatr Res 33 501-509.
12. SJ Cooper (1992) Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic. Br J Psychiatry 161 394-396.
13. TJ Crow and DJ Done (1992) Prenatal exposure to influenza does not cause schizophrenia. Br J Psychiatry 161 390-393.
14. PC Sham, E O'Callaghan, N Takei, et al. (1992) Schizophrenia following pre-natal exposure to influenza epidemics between 1939 and 1960. Br J Psychiatry 160 461-466.
15. RE Kendell and IW Kemp (1989) Maternal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 46 878-882.
16. J van Os and JP Selten (1998) Prenatal exposure to maternal stress and subsequent schizophrenia: the May 1940 invasion of The Netherlands. Br J Psychiatry 172 324-326.
17. A Myhrman, P Rantakallio, M Isohanni, et al. (1996) Unwantedness of a pregnancy and schizophrenia in the child. Br J Psychiatry 169 637-640.
18. MO Huttunen and P Niskanen (1978) Prenatal loss of father and psychiatric disorders. Arch Gen Psychiatry 35 429-431.
19. US Yaktin and S Labban (1992) Traumatic war: stress & schizophrenia. J Psychosoc Nurs Ment Health Serv 30(6), 29-33.
20. L Smits, C Pedersen, P Mortensen and J van Os (2004) Association between short birth intervals and schizophrenia in the offspring. Schizophr Res 70 49-56.
21. G Boog (2004) Obstetrical complications and subsequent schizophrenia in adolescent and young adult offsprings: is there a relationship? Eur J Obstet Gynecol Reprod Biol 114 130-136.
22. H Freeman (1994) Schizophrenia and city residence. Br J Psychiatry Suppl (23), 39-50.
23. PJ Harrison (1999) The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 122(Pt 4), 593-624.
24. F Plum (1972) Prospects for research on schizophrenia. 3. Neurophysiology: neuropathological findings. Neurosci Res Program Bull 10 384-388.
25. DA Lewis, T Hashimoto and DW Volk (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6 312-324.
26. DA Lewis, DW Volk and T Hashimoto (2004) Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 174 143-150.
27. GW Huntley, JC Vickers and JH Morrison (1997) Quantitative localization of NMDAR1 receptor subunit immunoreactivity in inferotemporal and prefrontal association cortices of monkey and human. Brain Res 749 245-262.
28. CG Hahn, HY Wang, DS Cho, et al. (2006) Altered neuregulin 1-erbB4 signaling con- tributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12 824-828.
29. K Talbot, WL Eidem, CL Tinsley, et al. (2004) Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 113 1353-1363.
30. Z Gu, Q Jiang, AK Fu, et al. (2005) Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J Neurosci 25 4974-4984.
31. D Gourion, C Goldberger, MC Bourdel, et al. (2004) Minor physical anomalies in patients with schizophrenia and their parents: prevalence and pattern of craniofacial abnormalities. Psychiatry Res 125 21-28.
32. ST Sivkov and VH Akabaliev (2003) Minor physical anomalies in schizophrenic patients and normal controls. Psychiatry 66 222-233.
33. M Trixler, T Tenyi, G Csabi and R Szabo (2001) Minor physical anomalies in schizophrenia and bipolar affective disorder. Schizophr Res 52 195-201.
34. JD Guy, LV Majorski, CJ Wallace and MP Guy (1983) The incidence of minor physical anomalies in adult male schizophrenics. Schizophr Bull 9 571-582.
35. B Ismail, E Cantor-Graae and TF McNeil (1998) Minor physical anomalies in schizophrenic patients and their siblings. Am J Psychiatry 155 1695-1702.
36. K Hata, J Iida, H Iwasaka, et al. (2003) Minor physical anomalies in childhood and adolescent onset schizophrenia. Psychiatry Clin Neurosci 57 17-21.
37. MF Green, P Satz, HV Soper and F Kharabi (1987) Relationship between physical anomalies and age at onset of schizophrenia. Am J Psychiatry 144 666-667.
38. MF Green, P Satz, DJ Gaier, et al. (1989) Minor physical anomalies in schizophrenia. Schizophr Bull 15 91-99.
39. P Firestone and S Peters (1983) Minor physical anomalies and behavior in children: a review. J Autism Dev Disord 13 411-425.
40. DL Braff, MA Geyer, GA Light, et al. (2001) Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res 49 171-178.
41. DL Braff, C Grillon and MA Geyer (1992) Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 49 206-215.
42. NR Swerdlow, DL Braff and MA Geyer (2000) Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol 11 185-204.
43. MA Geyer, K Krebs-Thomson, DL Braff and NR Swerdlow (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156 117-154.
44. BA Clementz, A Keil and J Kissler (2004) Aberrant brain dynamics in schizophrenia: delayed buildup and prolonged decay of the visual steady-state response. Brain Res Cogn Brain Res 18 121-129.
45. NN Boutros, G Zouridakis and J Overall (1991) Replication and extension of P50 findings in schizophrenia. Clin Electroencephalogr 22 40-45.
46. R Freedman, LE Adler, MC Waldo, et al. (1983) Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol Psychiatry 18 537-551.
47. Y Jin, SG Potkin, JV Patterson, et al. (1997) Effects of P50 temporal variability on sensory gating in schizophrenia. Psychiatry Res 70 71-81.
48. RJ Erwin, M Mawhinney-Hee, RC Gur and RE Gur (1991) Midlatency auditory evoked responses in schizophrenia. Biol Psychiatry 30 430-442.
49. C Siegel, M Waldo, G Mizner, et al. (1984) Deficits in sensory gating in schizophrenic patients and their relatives: evidence obtained with auditory evoked responses. Arch Gen Psychiatry 41 607-612.
50. D Umbricht, D Javitt, G Novak, et al. (1998) Effects of clozapine on auditory event-related potentials in schizophrenia. Biol Psychiatry 44 716-725.
51. TW Picton and SA Hillyard (1974) Human auditory evoked potentials. II. Effects of attention. Electroencephalogr Clin Neurophysiol 36 191-199.
52. TW Picton, SA Hillyard, HI Krausz and R Galambos (1974) Human auditory evoked potentials. I. Evaluation of components. Electroencephalogr Clin Neurophysiol 36 179-190.
53. J Gallinat, C Mulert, M Bajbouj, et al. (2002) Frontal and temporal dysfunction of auditory stimulus processing in schizophrenia. Neuroimage 17 110-127.
54. R Freedman, LE Adler, P Bickford, et al. (1994) Schizophrenia and nicotinic receptors. Harv Rev Psychiatry 2 179-192.
55. LE Adler, A Olincy, M Waldo, et al. (1998) Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24 189-202.
56. RJ Erwin, D Shtasel and RE Gur (1994) Effects of medication history on midlatency auditory evoked responses in schizophrenia. Schizophr Res 11 251-258.
57. NN Boutros, A Belger, D Campbell, et al. (1999) Comparison of four components of sensory gating in schizophrenic and normal subjects: a preliminary report. Psychiatry Res 88 119-130.
58. NN Boutros, O Korzyukov, B Jansen, et al. (2004) Sensory gating deficits during the mid-latency phase of information processing in medicated schizophrenia patients. Psychiatry Res 126 203-215.
59. T Rosburg (2004) Effects of tone repetition on auditory evoked neuromagnetic fields. Clin Neurophysiol 115 898-905.
60. BA Clementz, MA Geyer and DL Braff (1998) Multiple site evaluation of P50 suppression among schizophrenic and normal comparison subjects. Schizophr Res 30 71-80.
61. HJ Crawford, D McClain-Furmanski, N Castagnoli Jr and K Castagnoli (2002) Enhancement of auditory sensory gating and stimulus-bound gamma band (40 Hz) oscillations in heavy tobacco smokers. Neurosci Lett 317 151-155.
62. G Adler and WF Gattaz (1993) Auditory evoked potentials in schizophrenic patients before and during neuroleptic treatment: relationship to psychopathological state. Eur Arch Psychiatry Clin Neurosci 242 357-361.
63. SJ Siegel, CR Maxwell, S Majumdar, et al. (2005) Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials. Neuroscience 133 729-738.
64. LB Dixon, AF Lehman and J Levine (1995) Conventional antipsychotic medications for schizophrenia. Schizophr Bull 21 567-577.
65. SG Adams Jr and JT Howe (1993) Predicting medication compliance in a psychotic population. J Nerv Ment Dis 181 558-560.
66. JA Cramer and R Rosenheck (1998) Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49 196-201.
67. M Valenstein, LA Copeland, R Owen, et al. (2001) Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 62 545-551.
68. JP Lacro, LB Dunn, CR Dolder, et al. (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63 892-909.
69. DJ Corriss, TE Smith, JW Hull, et al. (1999) Interactive risk factors for treatment adherence in a chronic psychotic disorders population. Psychiatry Res 89 269-274.
70. R Rosenheck, D Leslie, R Keefe, et al. (2006) Barriers to employment for people with schizophrenia. Am J Psychiatry 163 411-417.
71. JM Davis, N Chen and ID Glick (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60 553-564.
72. J Geddes, N Freemantle, P Harrison and P Bebbington (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321 1371-1376.
73. CR Maxwell, SJ Kanes, T Abel and SJ Siegel (2004) Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience 129 101-107.
74. CR Maxwell, Y Liang, MP Kelly, et al. (2006) Mice expressing constitutively active G salpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients. Neuroscience 141 1257-1264.
75. G Remington (2003) Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target. J Psychiatry Neurosci 28 275-284.
76. JA Lieberman, TS Stroup, JP McEvoy, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 1209-1223.
77. ES Brodkin (2005) Quantitative trait locus analysis of aggressive behaviours in mice. Novartis Found Symp 268 57-69. discussion 69–77, 96–99
78. ES Brodkin, A Hagemann, SM Nemetski and LM Silver (2004) Social approach-avoidance behavior of inbred mouse strains towards DBA/2 mice. Brain Res 1002 151-157.
79. SJ Siegel, F Irani, CM Brensinger, et al. (2006) Prognostic variables at intake and long-term level of function in schizophrenia. Am J Psychiatry 163 433-441.
80. RC Gur, JD Ragland, PJ Moberg, et al. (2001) Computerized neurocognitive scanning: II. The profile of schizophrenia. Neuropsychopharmacology 25 777-788.
81. MF Green, RS Kern and RK Heaton (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72 41-51.
82. SR Marder, W Fenton and K Youens (2004) Schizophrenia, IX: Cognition in schizophrenia—the MATRICS initiative. Am J Psychiatry 161 25.
83. MF Green and KH Nuechterlein (2004) The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res 72 1-3.
84. MA Geyer and R Heinssen (2005) New approaches to measurement and treatment research to improve cognition in schizophrenia. Schizophr Bull 31 806-809.
85. LC Kopala (1996) Spontaneous and drug-induced movement disorders in schizophrenia. Acta Psychiatr Scand Suppl 389 12-17.
86. WS Fenton, RJ Wyatt and TH McGlashan (1994) Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry 51 643-650.
87. WS Fenton, CR Blyler, RJ Wyatt and TH McGlashan (1997) Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry 171 265-268.
88. WS Fenton (2000) Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 61(Suppl 4), 10-14.
89. J Delay, P Deniker, JM Harl and A Grasset (1952) [N-dimethylamino-prophylchlorophenothiazine (4560 RP) therapy of confusional states.]. Ann Med Psychol (Paris) 110 398-403.
90. J Delay, P Deniker and JM Harl (1952) [Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP).]. Ann Med Psychol (Paris) 110 112-117.
91. WW Shen (1999) A history of antipsychotic drug development. Compr Psychiatry 40 407-414.
92. P Seeman and T Lee (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188 1217-1219.
93. P Seeman, M Chau-Wong, J Tedesco and K Wong (1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A 72 4376-4380.
94. A Carlsson and M Lindqvist (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 20 140-144.
95. G Sedvall (1980) Relationships among biochemical, clinical, and pharmacokinetic variables in neuroleptic-treated schizophrenic patients. Adv Biochem Psychopharmacol 24 521-528.
96. L Farde, H Hall, E Ehrin and G Sedvall (1986) Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231 258-261.
97. L Farde, FA Wiesel, P Jansson, et al. (1988) An open label trial of raclopride in acute schizophrenia: confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology (Berl) 94 1-7.
98. J Kane, G Honigfeld, J Singer and H Meltzer (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45 789-796.
99. L Ereshefsky, MD Watanabe and TK Tran-Johnson (1989) Clozapine: an atypical antipsychotic agent. Clin Pharm 8 691-709.
100. AL Nordstrom, L Farde and C Halldin (1993) High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology (Berl) 110 365-367.
101. AL Nordstrom, L Farde, S Nyberg, et al. (1995) D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152 1444-1449.
102. C Trichard, ML Paillere-Martinot, D Attar-Levy, et al. (1998) Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 155 505-508.
103. L Rauser, JE Savage, HY Meltzer and BL Roth (2001) Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine 2C receptor. J Pharmacol Exp Ther 299 83-89.
104. PH Gruen, EJ Sachar, G Langer, et al. (1978) Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 35 108-116.
105. G Langer, EJ Sachar, PH Gruen and FS Halpern (1977) Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency. Nature 266 639-640.
106. SM Cheer and AJ Wagstaff (2004) Quetiapine: a review of its use in the management of schizophrenia. CNS Drugs 18 173-199.
107. BJ Kinon, VL Stauffer, HC McGuire, et al. (2003) The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients. J Am Med Dir Assoc 4 189-194.
108. HY Meltzer and SR McGurk (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25 233-255.
109. Keefe R, Gu H, Perkins D, et al., A comparison of the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis. In Proceedings of the 44th Annual Meeting of the American College of Neuropsychopharmacology. Nashville, TN: American College of Neuropsychopharmacology, 2005, p 127.
110. RS Keefe (2006) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Biol Psychiatry 59(Suppl), 965.
111. P Seeman, R Corbett and HH Van Tol (1997) Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 16 93-110. discussion 111–135.
112. AL Miller, CS Hall, RW Buchanan, et al. (2004) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 65 500-508.
113. DC Javitt (2006) Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 19 151-157.
114. I Zylberman, DC Javitt and SR Zukin (1995) Pharmacological augmentation of NMDA receptor function for treatment of schizophrenia. Ann N Y Acad Sci 757 487-491.
115. BN van Berckel, CN Evenblij, BJ van Loon, et al. (1999) d-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 21 203-210.
116. RB Rosse, SK Theut, M Banay-Schwartz, et al. (1989) Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmacol 12 416-424.
117. DC Javitt, I Zylberman, SR Zukin, et al. (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151 1234-1236.
118. DC Goff, L Herz, T Posever, et al. (2005) A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 179 144-150.
119. R Freedman, S Leonard, M Waldo, et al. (2006) Characterization of allelic variants at chromosome 15q14 in schizophrenia. Genes Brain Behav 5(Suppl 1), 14-22.
120. R Freedman, A Olincy, RG Ross, et al. (2003) The genetics of sensory gating deficits in schizophrenia. Curr Psychiatry Rep 5 155-161.
121. JK Simosky, KE Stevens, WR Kem and R Freedman (2001) Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. Biol Psychiatry 50 493-500.
122. LE Adler, EM Cawthra, KA Donovan, et al. (2005) Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry 162 386-388.
123. TJ Gould, SP Bizily, J Tokarczyk, et al. (2004) Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gs alpha. Neuropsychopharmacology 29 494-501.
124. MP Kelly, C Isiegas, YF Cheung, et al. (2007) Constitutive activation of G αs causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP. Neuropsychopharmacology 32 577-588.
125. S Kanes, J Tokarczyk, S Siegel, et al. (2007) Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 144 239-246.
126. H Stefansson, E Sigurdsson, V Steinthorsdottir, et al. (2002) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71 877-892.
127. H Stefansson, V Steinthorsdottir, TE Thorgeirsson, et al. (2004) Neuregulin 1 and schizophrenia. Ann Med 36 62-71.
128. BL Svarstad, TI Shireman and JK Sweeney (2001) Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 52 805-811.
129. JL Ayuso-Gutierrez and JM del Rio Vega (1997) Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 28 199-206.
130. J Menzin, L Boulanger, M Friedman, et al. (2003) Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 54 719-723. discussion 12–13.
131. JS McCombs, MB Nichol, GL Stimmel, et al. (1999) Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. J Clin Psychiatry 60(Suppl 19), 5-11.
132. DI Velligan, F Lam, L Ereshefsky and AL Miller (2003) Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 54 665-667.
133. MV Seeman (2001) Clinical trials in psychiatry: do results apply to practice? Can J Psychiatry 46 352-355.
134. PH Blachly (1965) Depot fluphenazine enanthate treatment of outpatient schizophrenics. J New Drugs 64 114-116.
135. RJ Laffan, JP High and JC Burke (1965) The prolonged action of fluphenazine enanthate in oil after depot injection. Int J Neuropsychiatry 1 300-306.
136. B Moldenhauer (1966) [Long-term therapy with depot-fluphenazine Dapotum in schizophrenia]. Med Welt 27 1477-1481.
137. WA McIlrath (1967) Experience with a depot phenothiazine in the treatment of schizophrenia. Med J Aust 1 760-762.
138. CE Adams, MK Fenton, S Quraishi and AS David (2001) Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179 290-299.
139. JM Kane, E Aguglia, AC Altamura, et al. (1998) Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 8 55-66.
140. SD Martin, SE Libretto, DJ Pratt, et al. (2003) Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Curr Med Res Opin 19 298-305.
141. TS Harrison and KL Goa (2004) Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 18 113-132.
142. AG Visco, AC Weidner, GW Cundiff and RC Bump (1999) Observed patient compliance with a structured outpatient bladder retraining program. Am J Obstet Gynecol 181 1392-1394.
143. SJ Siegel (2005) Extended release drug delivery strategies in psychiatry: theory to practice. Psychiatry 2005 2 22-31.
144. ML Hans, L Dan, KI Winey, et al. (2004) Daily to annual biodegradable drug delivery strategies for psychoactive compounds. SK Mallapragada (Ed.) Handbook of Biodegradable Polymeric Materials & Applications Stevenson Ranch, CA: American Scientific Publishers
145. SJ Siegel, KI Winey, RE Gur, et al. (2002) Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia. Neuropsychopharmacology 26 817-823.
146. AK Dash and GC Cudworth 2nd (1998) Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods 40 1-12.
147. F Fischel-Ghodsian and JM Newton (1993) Analysis of drug release kinetics from degradable polymeric devices. J Drug Target 1 51-57.
148. F Irani, M Dankert, C Brensinger, et al. (2004) Patient attitudes towards surgically implantable, long-term delivery of psychiatric medicine. Neuropsychopharmacology 29 960-968.